Merck's eye disease drug meets main goal in trial
MRK•Merck said remigromig met the main goal in a mid- to late-stage trial, demonstrating non-inferiority to ranibizumab in adults with diabetic macular edema.
1. Trial results
Merck said its drug remigromig met the main goal in a mid- to late-stage trial in adults with diabetic macular edema, demonstrating non-inferiority compared with control drug ranibizumab. The company said results will be presented at the upcoming annual meeting of the American Academy of Ophthalmology.
